Fcγ-Receptor IIIA Polymorphism p.158F Has No Negative Predictive Impact on Rituximab Therapy with and without Sequential Chemotherapy in CD20-Positive Posttransplant Lymphoproliferative Disorder

We retrospectively analyzed the p.V158F polymorphism of Fcγ-receptor IIIA (FCGR3A, CD16) in patients with PTLD treated with rituximab monotherapy. Previous reports had indicated that the lower affinity F allele affects rituximab-mediated antibody-dependent cellular cytotoxicity (ADCC) and is linked...

Descripción completa

Detalles Bibliográficos
Autores principales: Zimmermann, Heiner, Weiland, Theresa, Nourse, Jamie P., Gandhi, Maher K., Reinke, Petra, Neuhaus, Ruth, Karbasiyan, Mohsen, Gärtner, Barbara, Anagnostopoulos, Ioannis, Riess, Hanno, Trappe, Ralf U., Oertel, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2014
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987796/
https://www.ncbi.nlm.nih.gov/pubmed/24741582
http://dx.doi.org/10.1155/2014/264723

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3987796/
https://www.ncbi.nlm.nih.gov/pubmed/24741582
http://dx.doi.org/10.1155/2014/264723

Ejemplares similares